Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
ARQT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.99 - $17.70
Previous CloseN/A
Volume446.87K
Average Volume (3M)2.74M
Market Cap
$2.02B
Enterprise Value$1.03B
Total Cash (Recent Filing)$71.33M
Total Debt (Recent Filing)$110.58M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
May 20, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding118,638,240
10 Day Avg. Volume3,005,072
30 Day Avg. Volume2,744,411
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.27
Price to Cash Flow (P/CF)-674.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda-9.42
Forecast
1Y Price Target
$18.67Price Target Upside9.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Earnings Exceed ExpectationsZoryve franchise sales for 4Q24 exceeded expectations, reaching $69.4M, which is higher than the pre-announced product revenues.
Prescription GrowthZoryve prescriptions rebounded with a 7.0% increase in total prescriptions and a 7.7% increase in new prescriptions.
Sales ForecastThe forecast for 2025 Zoryve franchise sales has been increased to approximately $299M, surpassing the consensus estimate.
Bears Say
Insurance Coverage GapManagement expects insurance switching to lead to a coverage gap affecting Zoryve prescriptions in the first quarter.
Prescription DeclinePrescriptions for the Zoryve franchise were down likely due to tough comps and a general softness in the I&I category.
Prescription DecreaseTRxs for the Zoryve franchise were down 7.5% and NRxs were down 3.9% compared to increases in the prior week.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $6.99 and its highest was $17.70 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $2.02B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 20, 2025 which is in 54 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 25, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.255 by $0.165.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -0.21.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 118,638,240 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.255. Following the earnings report the stock price went up 8.361%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
---
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (9.12% Upside)
$18.67 (9.12% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 54.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 39.1%
Last 30 Days ▲ 39.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.77%
12-Months-Change
Fundamentals
Return on Equity
-113.76%
Trailing 12-Months
Asset Growth
2.20%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics (ARQT) is a biopharmaceutical company focused on developing innovative therapies for dermatological diseases and conditions. The company is committed to addressing unmet needs in dermatology by advancing a diverse pipeline of topical treatments. Arcutis aims to improve the standard of care for patients with skin diseases, such as psoriasis and atopic dermatitis, through its core product offerings.
---
ARQT Company Deck
---
ARQT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance driven by significant revenue growth, successful product launches, and expanded Medicaid coverage. However, challenges such as Q1 revenue fluctuations, Medicare Part D negotiations, and minimal contribution from the Kowa partnership were noted. The sentiment is balanced with optimism for future growth.Read More>---
ARQT Stock 12 Month Forecast
Average Price Target
$18.67
▲(9.12% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Xoma
―
Aclaris Therapeutics
―
Kura Oncology
―
Journey Medical Corp
―
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+53.56%
reiterated a buy rating 30 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +53.56% per trade.
---